Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 12/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | HPGD | P15428 | 5/20 | 0.54 |
| ▸ | GAA | P10253 | 5/20 | 0.54 |
| ▸ | GLA | P06280 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | ATM | Q13315 | 4/20 | 0.48 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.41 |
| ▸ | UPP1 | Q16831 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2592915 | 0.81 | KDM4E (0.52) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL1694465 | 0.77 | KDM4E (0.62) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL15647458 | 0.75 | KDM4E (0.59) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL2587156 | 0.74 | KDM4E (0.57) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL2593981 | 0.74 | KDM4E (0.60) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL2587537 | 0.73 | KDM4E (0.71) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL13277489 | 0.71 | KDM4E (0.54) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL21489613 | 0.71 | KDM4E (0.59) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL21419369 | 0.71 | KDM4E (0.51) | KDM4EALDH1A1HPGDGAAGLA | |
| SCHEMBL10747601 | 0.70 | KDM4E (0.66) | KDM4EALDH1A1HPGDGAAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9969716-B2 | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969716-B2 | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969716-B2 | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2018-05-15 | — | — | US | disclosed |
| US-20160185757-A1 | INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185757-A1 | INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| US-20160185757-A1 | INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| EP-3033334-A1 | INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | Constellation Pharmaceuticals, Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015023915-A1 | INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015023915-A1 | INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2015-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185757-A1 | INDOLE DERIVATIVES AS MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF | INMT, HNMT, NNMT | KDM4E 106/4885ALDH1A1 493/4885HPGD 255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.